Početna stranicaMEHCQ • OTCMKTS
add
23andMe Holding Co.
Preth. zaklj. cijena
1,17 $
Dnevni raspon
1,07 $ - 1,18 $
Godišnji raspon
0,48 $ - 12,76 $
Tržišna kapitalizacija
30,85 mil. USD
Prosječna količina
8,09 mil.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
OTCMKTS
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | pro 2024.info | Godišnja promjena |
---|---|---|
Prihod | 60,26 mil. | 34,67 % |
Operativni troškovi | 65,06 mil. | −22,18 % |
Neto dohodak | −53,04 mil. | 80,92 % |
Neto profitabilnost | −88,01 | 85,83 % |
Zarada po dionici | — | — |
EBITDA | −21,80 mil. | 62,70 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | pro 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 79,35 mil. | −67,27 % |
Ukupna imovina | 277,42 mil. | −54,39 % |
Ukupne obveze | 214,70 mil. | −7,06 % |
Ukupni kapital | 62,72 mil. | — |
Dionice u optjecaju | 26,83 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,50 | — |
Povrat imovine | −21,15 % | — |
Povrat kapitala | −42,49 % | — |
Tok novca
Neto promjena novca
(USD) | pro 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −53,04 mil. | 80,92 % |
Gotovina od poslovanja | −44,65 mil. | −270,23 % |
Gotovina iz ulaganja | 887,00 tis. | 144,09 % |
Gotovina iz financiranja | −19,00 tis. | −118,10 % |
Neto promjena novca | −43,79 mil. | −213,47 % |
Slobodan tok novca | −20,18 mil. | −469,10 % |
Više
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Osnovano
tra 2006
Web-lokacija
Zaposlenici
571